ClinicalTrials.gg
CompletedNCT07121192Updated May 28, 2026

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

A Phase 2 interventional study of Flu mRNA (Formulation A) and Flu mRNA (Formulation B) in Influenza, Human, sponsored by GlaxoSmithKline. Completed at 22 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
776
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 187 studies in Influenza, Human by GlaxoSmithKline — 3 open to participants now, 3 under way, 2 of them phase 3. Influenza, Human · GlaxoSmithKline.

Enrollment
50th of 165
776 · median 324
Started
2025
with 1 other
Phase 2
53 of 187
none open now
Registered
183rd of 187
by date

Among the 187 studies in Influenza, Human by GlaxoSmithKline, this one is the 50th largest by enrollment of the 165 interventional ones that give a count, is one of 2 that started in 2025, is one of 53 in phase 2, and was the 183rd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

3 of the 187 studies in Influenza, Human by GlaxoSmithKline are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Influenza, Human by GlaxoSmithKline, or all of them as a file.
02

Study summary

"The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults."

03

Conditions studied

  • Influenza, Human

Keywords

  • Influenza
  • Human
  • Virus Diseases
  • Infections
  • mRNA vaccine
  • Younger Adults
  • Older Adults
  • multivalent seasonal influenza vaccine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, attendance to study contacts and study site visits, and ability to access and utilize a phone or other electronic communications) independently or with the assistance of a caregiver.
  2. Written (physically, or digitally) obtained from the participant prior to performance of any study-specific procedure.
  3. A male or female at least 18 YOA at the time of the screening.
  4. Healthy participants or medically stable patients as established by medical history, and clinical examination. Participants with chronic medical conditions with or without specific treatment (e.g., chronic metabolic, cardiac, pulmonary, renal, neurologic, and hematologic diseases) are allowed to participate in this study, if considered by the investigator as medically stable. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during 3 months before enrollment.
  5. Female participants of non- may be enrolled in the clinical study.
  6. Female participants of childbearing potential may be enrolled in the clinical study, if the participant:

    • Has practiced adequate for at least 4 weeks prior to the study intervention administration, and
    • Has a negative urine pregnancy test within 24 hours prior to the study intervention administration, and
    • Has agreed to continue adequate contraception for at least 8 weeks after study intervention administration.
  7. (BMI) between18 kg/m\^² and 33kg/m\^².

Exclusion criteria

Exclusion Criteria:

  1. Where applicable, FDA toxicity grades will be exclusionary.
  2. or immunodeficient conditions by history/exam; stable -positive individuals on therapy can participate.
  3. History of Guillain-Barré Syndrome within 6 weeks of receiving any vaccine.
  4. Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 1 year).
  5. to latex.
  6. History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
  7. History of hypersensitivity or severe allergic reaction to any previous influenza vaccine.
  8. History of hypersensitivity or severe allergic reaction to any previous mRNA vaccine.
  9. History of or current suspicion of myocarditis or pericarditis, or medical issues increasing such risks.
  10. Condition that in the judgment of the investigator would make intramuscular injection unsafe.
  11. Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study.
  12. History of confirmed influenza infection by local health authority-approved testing methods within 180 days prior to study intervention administration.
  13. Use of any or non-registered product (drug, vaccine or invasive medical device) other than the study intervention(s) during the period beginning 28 days before the dose of study intervention(s) (Day -28 to Day 1), or their planned use during the study period.
  14. Administration of an influenza vaccine within 180 days before the study intervention administration or planned administration prior to Visit 4 (Day 29) during the study.
  15. Administration of any non-live attenuated non-study vaccine in the period starting 14 days before the study intervention administration, or planned administration within 14 days after study intervention administration.
  16. Administration of any live attenuated and/or mRNA non-study non-influenza vaccine in the period starting 28 days before the study intervention administration, or planned administration within 28 days after study intervention administration.
  17. Chronic administration of immune-modifying drugs.
  18. Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the study intervention, or planned administration during the study period.
  19. Administration of anti-tumoral medication during the period starting 90 days before the study intervention or planned administration during the study period.
  20. Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention.
  21. Any study personnel or their immediate dependents, family, or household members.
  22. Has a history of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  23. Participant is pregnant.
  24. Participant is breastfeeding or will (re)start breastfeeding during the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
776 participants (actual)

Study arms

  • Experimental
    Flu mRNA_1_YA

    Eligible Younger Adults (YA) participants receive a single dose of Flu mRNA Formulation A (GSK6479720A) as study intervention at Day 1.

    Biological: Flu mRNA (Formulation A)

  • Experimental
    Flu mRNA_2_YA

    Eligible YA participants receive a single dose of Flu mRNA Formulation B (GSK6479715A) as study intervention at Day 1.

    Biological: Flu mRNA (Formulation B)

  • Active comparator
    Comparator_1_YA

    Eligible YA participants receive a single dose of comparator 1 at Day 1.

    Combination Product: Comparator 1

  • Active comparator
    Comparator_2_YA

    Eligible YA participants receive a single dose of comparator 2 at Day 1.

    Combination Product: Comparator 2

  • Experimental
    Flu mRNA_1_OA

    Eligible Older Adults (OA) participants receive a single dose of Flu mRNA Formulation A (GSK6479720A) as study intervention at Day 1.

    Biological: Flu mRNA (Formulation A)

  • Experimental
    Flu mRNA_2_OA

    Eligible OA participants receive a single dose of Flu mRNA Formulation B (GSK6479715A) as study intervention at Day 1.

    Biological: Flu mRNA (Formulation B)

  • Experimental
    Comparator_1_OA

    Eligible OA participants receive a single dose of comparator 1 at Day 1.

    Combination Product: Comparator 1

  • Active comparator
    Comparator_2_OA

    Eligible OA participants receive a single dose of comparator 2 at Day 1.

    Combination Product: Comparator 2

  • Active comparator
    Comparator_3_OA

    Eligible OA participants receive a single dose of comparator 3 at Day 1.

    Combination Product: Comparator 3

Interventions

  • BiologicalFlu mRNA (Formulation A)

    One dose of Flu mRNA (Formulation A) received intramuscularly.

    Also known as: GSK6479720A

  • BiologicalFlu mRNA (Formulation B)

    One dose of Flu mRNA (Formulation B) received intramuscularly.

    Also known as: GSK6479715A

  • Combination productComparator 1

    One dose of Comparator 1 received intramuscularly.

  • Combination productComparator 2

    One dose of Comparator 2 received intramuscularly.

    Also known as: Click here to enter text.

  • Combination productComparator 3

    One dose of Comparator 3 received intramuscularly.

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) Ratio of Antigen 1 Titer

    Time frame: At Day 29

  2. Geometric Mean Increase (GMI) of Antigen 1 Titer

    Time frame: From Day 1 to Day 29

  3. Percentage of Participants with Antigen 1 Seroconversion Rate (SCR)

    Time frame: From Day 1 to Day 29

  4. Percentage of Participants with Antigen 1 Seroprotection Rate (SPR)

    Time frame: At Day 1 and Day 29

  5. Number of Participants with Solicited Administration Site Adverse Events (Aes)

    The solicited administration site AEs considered are pain, redness, swelling and lymphadenopathy.

    Time frame: From Day 1 to Day 7

  6. Number of Participants with Solicited Systemic Aes

    The solicited systemic AEs considered are fever, headache, fatigue, myalgia, arthralgia and chills. Fever is defined as temperature greater than or equal to (\>=) 38 °C/100.4°F regardless the location of measurement.

    Time frame: From Day 1 to Day 7

  7. Number of Participants with Unsolicited Aes

    An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.

    Time frame: From Day 1 to Day 28

  8. Number of Participants with Serious Adverse Events (SAEs)

    SAE is an AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or other situations that are considered serious per medical or scientific judgment.

    Time frame: From Day 1 to Day 181 (study end)

  9. Number of Participants with Adverse Events of Special Interest (AESIs)

    Time frame: From Day 1 to Day 181 (study end)

  10. Number of Participants with Medically Attended Adverse Events (MAAEs)

    A MAAE is an AE for which the participant received medical attention including any symptom or illness requiring hospitalization, or an emergency room visit, or visit to/by a healthcare professional.

    Time frame: From Day 1 to Day 181 (study end)

  11. Number of Participants with any Laboratory abnormalities

    Click here to enter text.

    Time frame: From Day 1 to Day 29

Secondary outcomes

  1. GMT Ratio of Antigen 2 Titer

    Time frame: At Day 29

  2. GMI of Antigen 2 Titer

    Time frame: From Day 1 to Day 29

  3. Percentage of Participants with Antigen 2 SCR

    Time frame: From Day 1 to Day 29

07

Study locations

22 sites
  • GSK Investigational Site
    Anniston, Alabama 36207, United States
  • GSK Investigational Site
    Fair Oaks, California 95628, United States
  • GSK Investigational Site
    San Diego, California 92120, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    Walnut Creek, California 94598, United States
  • GSK Investigational Site
    Hialeah, Florida 33012, United States
  • GSK Investigational Site
    Jupiter, Florida 33458, United States
  • GSK Investigational Site
    Miami, Florida 33186, United States
  • GSK Investigational Site
    Stockbridge, Georgia 30281, United States
  • GSK Investigational Site
    Valparaiso, Indiana 46383, United States
  • GSK Investigational Site
    Lenexa, Kansas 66219, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01103, United States
  • GSK Investigational Site
    Carson City, Nevada 89706, United States
  • GSK Investigational Site
    Rochester, New York 14609, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27408, United States
  • GSK Investigational Site
    Cleveland, Ohio 44122, United States
  • GSK Investigational Site
    North Charleston, South Carolina 29405, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    DeSoto, Texas 75115, United States
  • GSK Investigational Site
    Fort Worth, Texas 76135, United States
  • GSK Investigational Site
    Newport News, Virginia 23606, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in May 2026, 8 months.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 8 months is above that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2025
First posted
Aug 13, 2025
StartActual
Aug 25, 2025
Primary completionActual
May 11, 2026
CompletionActual
May 11, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07121192
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Aug 25, 2025
Primary completion
May 11, 2026
Completion
May 11, 2026
Last update
May 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion